Banked Primary Progenitor Cells for Allogeneic Intervertebral Disc (IVD) Therapy: Preclinical Qualification and Functional Optimization within a Cell Spheroid Formulation Process
Authors:
- Annick JeanneratAJAnnick Jeannerat
- Cédric PeneveyreCPCédric Peneveyre
- Sandra JaccoudSJSandra Jaccoud
- Virginie PhilippeVPVirginie Philippe
- Corinne ScalettaCSCorinne Scaletta
- Nathalie Hirt-BurriNHNathalie Hirt-Burri
- Philippe Abdel-SayedPhilippe Abdel-Sayed
- Robin MartinRMRobin Martin
- Lee Ann ApplegateLee Ann Applegate
- Dominique P. PiolettiDPDominique P. Pioletti
- Alexis LaurentALAlexis Laurent
Open Access
- 29 September 2024
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (10) , 1274
Abstract
Background/Objectives: Biological products are emerging as therapeutic management options for intervertebral disc (IVD) degenerative affections and lower back pain. Autologous and allogeneic cell therapy protocols have been clinically implemented for IVD repair. Therein, several manufacturing process design considerations were shown to significantly influence clinical outcomes. The primary objective of this study was to preclinically qualify (chondrogenic potential, safety, resistance to hypoxic and inflammatory stimuli) cryopreserved primary progenitor cells (clinical grade FE002-Disc cells) as a potential cell source in IVD repair/regeneration. The secondary objective of this study was to assess the cell source’s delivery potential as cell spheroids (optimization of culture conditions, potential storage solutions). Methods/Results: Safety (soft agar transformation, β-galactosidase, telomerase activity) and functionality-related assays (hypoxic and inflammatory challenge) confirmed that the investigated cellular active substance was highly sustainable in defined cell banking workflows, despite possessing a finite in vitro lifespan. Functionality-related assays confirmed that the retained manufacturing process yielded strong collagen II and glycosaminoglycan (GAG) synthesis in the spheroids in 3-week chondrogenic induction. Then, the impacts of various process parameters (induction medium composition, hypoxic incubation, terminal spheroid lyophilization) were studied to gain insights on their criticality. Finally, an optimal set of technical specifications (use of 10 nM dexamethasone for chondrogenic induction, 2% O2 incubation of spheroids) was set forth, based on specific fine tuning of finished product critical functional attributes. Conclusions: Generally, this study qualified the considered FE002-Disc progenitor cell source for further preclinical investigation based on safety, quality, and functionality datasets. The novelty and significance of this study resided in the establishment of defined processes for preparing fresh, off-the-freezer, or off-the-shelf IVD spheroids using a preclinically qualified allogeneic human cell source. Overall, this study underscored the importance of using robust product components and optimal manufacturing process variants for maximization of finished cell-based formulation quality attributes.Keywords
Funding Information
- S.A.N.T.E and Sandoz Foundations
This publication has 90 references indexed in Scilit:
- Targeted screening of inflammatory mediators in spontaneous degenerative disc disease in dogs reveals an upregulation of the tumor necrosis superfamilyJOR SPINE, 2023
- Preclinical to clinical translation for intervertebral disc repair: Effects of species‐specific scale, metabolism, and matrix synthesis rates on cell‐based regenerationJOR SPINE, 2023
- The Regulation of Cell Therapy and Gene Therapy Products in Switzerland2023
- Effect of different cryopreservation media on human nucleus pulposus cells' viability and trilineage potentialJOR SPINE, 2021
- Advancing cell therapies for intervertebral disc regeneration from the lab to the clinic: Recommendations of the ORS spine sectionJOR SPINE, 2018
- Discogenic cell transplantation directly from a cryopreserved state in an induced intervertebral disc degeneration canine modelJOR SPINE, 2018
- A prospective randomized multicenter phase I/II clinical trial to evaluate safety and efficacy of NOVOCART disk plus autologous disk chondrocyte transplantation in the treatment of nucleotomized and degenerative lumbar disks to avoid secondary disease: safety results of Phase I—a short reportNeurosurgical Review, 2016
- Treatment of the degenerated intervertebral disc; closure, repair and regeneration of the annulus fibrosusJournal of Tissue Engineering and Regenerative Medicine, 2014
- World Medical Association Declaration of HelsinkiJAMA, 2013
- Clinical experience in cell-based therapeutics: intervention and outcomeEuropean Spine Journal, 2006